Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Sales Analysis
JNJ logo

Johnson & Johnson Sales Climb 6.8% to $24B Despite Biosimilar Hits

JNJ10-QFiling Date: 10/22/2025
Johnson & Johnson
Description

What this story covers

Johnson & Johnson reported Q3 sales of $24B, up 6.8%, driven by oncology and neuroscience growth offsetting STELARA biosimilar losses. Innovative Medicine and MedTech segments advanced, bolstered by acquisitions like Intra-Cellular ($14.5B). Strong liquidity ($18.6B) supports dividends ($9.3B YTD) and reserves for talc ($3.8B). Risks include litigation and regulatory pressures, but margins expanded amid global execution.

Story snapshot

CompanyJohnson & Johnson
TickerJNJ
VariantStandard detailed
Duration14:58
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000200406-25-000209

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in